Physician profile
Maqbool Arshad
NPI 1518999655
$3,395.31
in general payments reported to CMS, 2019-2025
21 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $483 · 2021: $759 · 2022: $1,059 · 2023: $221 · 2024: $61.73 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $298.82 |
| Education | $154.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $898.38 | 2019-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $397.86 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $390.72 | 2019-2024 | Breztri |
| Grifols USA, LLC | $310.19 | 2019-2023 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.98 | 2019-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $185.76 | 2019-2023 | Dupixent |
| Genzyme Corporation | $160.08 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $141.70 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $131.07 | 2019-2022 | |
| Inspire Medical Systems, INC. | $119.91 | 2022 | |
| Mylan Specialty L.P. | $69.32 | 2019-2021 | |
| Verona Pharma, INC. | $54.23 | 2025 | Ohtuvayre |
| Electromed, INC. | $41.76 | 2021 | |
| Philips North America LLC | $41.54 | 2022 | |
| Lilly USA, LLC | $38.87 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.52 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.46 | 2022 | |
| Circassia INC. | $17.06 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.67 | 2023 | Xifaxan |
| Novo Nordisk INC | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maqbool Arshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.